Royalty Pharma Plc Stock Today
| RPRX Stock | USD 31.11 0.68 2.14% |
PerformanceGood
| Odds Of DistressLow
|
Royalty Pharma is trading at 31.11 as of the 5th of April 2025; that is 2.14 percent decrease since the beginning of the trading day. The stock's open price was 31.79. Royalty Pharma has only a 7 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 5th of January 2025 and ending today, the 5th of April 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 1993 | Category Healthcare | Classification Health Care |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company was founded in 1996 and is based in New York, New York. Royalty Pharma is traded on NASDAQ Exchange in the United States.. The company has 433.32 M outstanding shares of which 15.57 M shares are at this time shorted by private and institutional investors with about 3.31 trading days to cover. More on Royalty Pharma Plc
Moving together with Royalty Stock
Moving against Royalty Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Royalty Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Pharmaceutical, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRoyalty Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Royalty Pharma's financial leverage. It provides some insight into what part of Royalty Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Royalty Pharma Plc (RPRX) is traded on NASDAQ Exchange in USA. It is located in 110 East 59th Street, New York, NY, United States, 10022 and employs 16 people. Royalty Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 17.93 B. Royalty Pharma Plc conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 433.32 M outstanding shares of which 15.57 M shares are at this time shorted by private and institutional investors with about 3.31 trading days to cover.
Royalty Pharma Plc currently holds about 1.47 B in cash with 2.77 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34.
Check Royalty Pharma Probability Of Bankruptcy
Ownership AllocationRoyalty Pharma owns a total of 433.32 Million outstanding shares. The majority of Royalty Pharma Plc outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Royalty Pharma Plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Royalty Pharma. Please pay attention to any change in the institutional holdings of Royalty Pharma Plc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Royalty Ownership Details
Royalty Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-12-31 | 3.7 M | |
| Northern Trust Corp | 2024-12-31 | 3.3 M | |
| Gmt Capital Corp | 2024-12-31 | 3.3 M | |
| Deutsche Bank Ag | 2024-12-31 | 3.2 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 3.1 M | |
| Bank Of America Corp | 2024-12-31 | 3 M | |
| Newsouth Capital Management Inc | 2024-12-31 | 3 M | |
| Citadel Advisors Llc | 2024-12-31 | 2.9 M | |
| Patients Capital Management Llc | 2024-12-31 | 2.9 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 39.5 M | |
| Vanguard Group Inc | 2024-12-31 | 37.4 M |
Royalty Pharma Historical Income Statement
Royalty Stock Against Markets
Royalty Pharma Corporate Management
| Eric Schneider | Senior Officer | Profile | |
| George Lloyd | Executive Officer | Profile | |
| Marshall MD | Executive Investments | Profile | |
| Sandy Balkin | Senior Analytics | Profile | |
| Sara Klymkowsky | Senior Investments | Profile | |
| Ashwin MD | Executive Investments | Profile |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.